A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-55
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).
Eligibility criteria
Qualifiers
Age ≥ 18 years of age.
Newly diagnosed CD19+ and CD22+ B-ALL with the following characteristics
Patients ≥55 years old, OR
ECOG performance status of 2 or more
Disqualifiers
Patients with Burkitt's lymphoma, T-ALL, CML in lymphoid blast crisis and mixed phenotype acute leukemia (MPAL).
Patients with newly diagnosed B-ALL who received prior treatments, with the exception of corticosteroid, hydroxyurea, or one dose of vincristine, are ineligible.
Patients with Ph+ B-ALL by FISH or RT PCR.
ECOG performance status >3.
Trial design
Treatments tested in this trial
- Blinatumomab Injection
Treatment groups
26 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov